Key clinical point: Lung CT scores remain stable or improve following hematopoietic stem cell transplantation in patients with scleroderma-related interstitial lung disease when compared against monthly cyclophosphamide treatments.
Major finding: Quantitative interstitial lung disease scores decreased by 7% at 54 months in hematopoietic stem cell transplant patients versus no change in those who received cyclophosphamide (P = .024).
Study details: A study of 75 patients from the SCOT trial.
Disclosures: The investigators reported having no relevant disclosures.
Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901.